Saxenda refill excitement: what the GLP-1 hype misses

What did @celinaestrada64 actually say?

After a two-week break from Saxenda (liraglutide), Celina gained roughly six pounds and noticed her appetite returning fast. She restarted at 3 mg and is hoping the medication will "kick in like it did last time" and produce rapid early weight loss again. She also mentioned eating more, waking up hungry, and feeling the difference in appetite regulation within days of stopping the injection.

This is a pretty honest account of what stopping a GLP-1 receptor agonist actually feels like. She is not selling anything or overclaiming. She is tracking her own experience week by week, which is more transparency than you get from most weight loss content on this platform.

Does the science back this up?

Yes, and it is not subtle. The appetite return she describes is well-documented in clinical literature, and the weight regain trajectory is consistent with what trials show.

A 2022 paper by Wilding et al. in Diabetes, Obesity and Metabolism followed patients after stopping semaglutide (a closely related GLP-1 agonist) and found that participants regained about two-thirds of their lost weight within a year of discontinuation. That is a different drug, but the mechanism is shared: GLP-1 receptor agonists suppress appetite pharmacologically, and when the drug clears, the suppression clears with it.

Liraglutide (Saxenda) has a half-life of roughly 13 hours, meaning it clears the system in two to three days. The 2021 SCALE Maintenance trial (Davies et al., The Lancet) showed that patients who stopped liraglutide after a run-in period regained significantly more weight than those who continued. Hunger returning within days of stopping, as Celina experienced, is physiologically expected, not a personal failure.

What did they get wrong (or right)?

The claim that earned the most scrutiny here is the idea that taking two weeks off might "kickstart" weight loss the way a one-week break apparently did before. That is not really how liraglutide works, and expecting a restart bonus is not supported by evidence.

Weight loss with GLP-1 agonists tends to follow a dose-response curve and a time curve. The early weeks often show faster loss partly because of fluid shifts and caloric deficit novelty, not because the drug is freshest. Restarting after a gap does not reset those mechanisms. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed weight loss was progressive and sustained with continuous use, not cyclical.

What she got right: the observation that appetite suppression fades fast after stopping is accurate. Her description of hunger timing shifting from 4 PM back to the morning is a real clinical signal, not placebo. She also correctly noted she went back to 3 mg, though we cannot comment on whether that dose is clinically appropriate for her specifically since that is a provider decision.

What should you actually know?

If you are on a GLP-1 medication and you stop, even briefly, expect appetite to return and expect some weight regain. This is biology, not willpower failure. The drug is doing what it is supposed to do pharmacologically, and when it is gone, so is that effect.

A few things worth knowing if you are following a similar journey. First, the "kickstart" concept is not validated. Restarting a medication after a gap is not equivalent to first starting it. Second, GLP-1 medications are generally intended for continuous use under medical supervision, not on-and-off cycling. Stopping and starting without guidance can complicate titration and side effect management. Third, the combination of medication plus exercise that Celina mentions has real support: a 2023 meta-analysis by Zhao et al. in Obesity Reviews found that adding structured exercise to GLP-1 therapy improved body composition outcomes beyond medication alone. Getting back to the gym, as she plans to, is genuinely useful, not just motivational filler.

Her experience is real. The science behind it is clear. The "kickstart" framing is the one part that deserves a skeptical read.